Antisense Therapeutics Ltd (ANP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Antisense Therapeutics Ltd (ANP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10029
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on the development of antisense drugs in the areas of cancer treatment, respiratory diseases, immunology disorders and rare diseases. Antisense Therapeutics’s development pipeline comprises of ATL1103 which blocks GHr production and lowers blood IGF-I levels and is a potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being development for the treatment of multiple sclerosis and also pre-clinical development stage for the treatment of asthma as an inhalation; and ATL1101 which is being investigated for the potential treatment for prostate cancer. Antisense Therapeutics is headquartered in Toorak, Victoria, Australia.

Antisense Therapeutics Ltd (ANP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Antisense Therapeutics Forms Joint Venture With Tianjin International Joint Academy 10
Licensing Agreements 12
Cortendo Enters into Licensing Agreement with Antisense Therapeutics 12
Equity Offering 14
Antisense Therapeutics Raises USD3.4 Million in Rights Offering of Shares 14
Antisense Therapeutics Raises USD0.4 Million in Institutional Private Placement of Shares 15
Antisense Therapeutics Raises USD0.8 Million in Private Placement of Shares 17
Antisense Therapeutics to Raise USD1.3 Million in Private Placement of Shares 19
Antisense Therapeutic Completes Rights Issue Of Common Stock For US$0.6 Million 21
Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For US$2.04 Million 22
Antisense Therapeutics Ltd – Key Competitors 23
Antisense Therapeutics Ltd – Key Employees 24
Antisense Therapeutics Ltd – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Product News 26
10/30/2017: ATL1102 ‘Black Hole’ MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting 26
Jun 16, 2017: Antisense Therapeutics: Positive effects seen with ATL1102 on Multiple Sclerosis “Black Hole” brain lesions 27
Product Approvals 28
Jun 26, 2017: ATL1102 for Multiple Sclerosis–Phase IIb Investigational New Drug Application Submitted to the FDA 28
Apr 24, 2017: ATL1102 for Multiple Sclerosis – Phase IIb Investigational New Drug Submission 29
Clinical Trials 30
Feb 28, 2018: Approval received for Phase II trial of ATL1102 in Duchenne Muscular Dystrophy 30
Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update 31
Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update 32
Oct 02, 2017: Antisense Therapeutics Provides Update on Multiple Sclerosis Drug Candidate ATL1102 33
Sep 12, 2017: Antisense Therapeutics Announces Update on ATL1102 34
Jul 27, 2017: Antisense Therapeutics Provides Phase IIb Trial Update on ATL1102 for Multiple Sclerosis 35
Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy 36
Jun 16, 2017: Positive effects seen with ATL1102 on Multiple Sclerosis “Black Hole” brain lesions 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Antisense Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Antisense Therapeutics Forms Joint Venture With Tianjin International Joint Academy 10
Cortendo Enters into Licensing Agreement with Antisense Therapeutics 12
Antisense Therapeutics Raises USD3.4 Million in Rights Offering of Shares 14
Antisense Therapeutics Raises USD0.4 Million in Institutional Private Placement of Shares 15
Antisense Therapeutics Raises USD0.8 Million in Private Placement of Shares 17
Antisense Therapeutics to Raise USD1.3 Million in Private Placement of Shares 19
Antisense Therapeutic Completes Rights Issue Of Common Stock For US$0.6 Million 21
Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For US$2.04 Million 22
Antisense Therapeutics Ltd, Key Competitors 23
Antisense Therapeutics Ltd, Key Employees 24

List of Figures
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Antisense Therapeutics Ltd (ANP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NeoGenomics Inc (NEO):医療機器:M&Aディール及び事業提携情報
    Summary NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immuno …
  • Petroleo Brasileiro SA (PETR4):企業の財務・戦略的SWOT分析
    Petroleo Brasileiro SA (PETR4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bioasis Technologies Inc (BTI):企業の財務・戦略的SWOT分析
    Summary Bioasis Technologies Inc (BTI) operates as a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents …
  • SP Transmission plc:企業の戦略的SWOT分析
    SP Transmission plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • The Whiting-Turner Contracting Co:企業の戦略・SWOT・財務情報
    The Whiting-Turner Contracting Co - Strategy, SWOT and Corporate Finance Report Summary The Whiting-Turner Contracting Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Asatsu-DK Inc. (9747):企業の財務・戦略的SWOT分析
    Asatsu-DK Inc. (9747) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Teijin Limited:企業のM&A・事業提携・投資動向
    Teijin Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Teijin Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • MAXrad SOFTware (India) Pvt. Ltd.:企業の戦略・SWOT・財務情報
    MAXrad SOFTware (India) Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary MAXrad SOFTware (India) Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Clover Corp Ltd (CLV):企業の財務・戦略的SWOT分析
    Summary Clover Corp Ltd (Clover), a subsidiary of Washington H. Soul Pattinson and Company Ltd, is a developer of science-based bioactives. The company offers products such as DHA oils, DHA powders and microencapsulation. It delivers bioactive ingredients through encapsulation. Clover’s refined tuna …
  • NovaBay Pharmaceuticals Inc (NBY):医療機器:M&Aディール及び事業提携情報
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that discovers and develops eyecare products. The company’s products include skin and wound cleanser, daily lid and lash hygiene spray solutions, and cosetic procedures. Its daily lid a …
  • Diagnostics For All Inc:企業の製品パイプライン分析2018
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • Green Plains Inc.:企業の戦略・SWOT・財務情報
    Green Plains Inc. - Strategy, SWOT and Corporate Finance Report Summary Green Plains Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • HoMedics USA LLC:企業の戦略的SWOT分析
    HoMedics USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • National Jewish Health-製薬・医療分野:企業M&A・提携分析
    Summary National Jewish Health (NJH), formerly National Jewish Medical and Research Center is a healthcare center that offers treatment of pulmonary, cardiac, immune and related disorders. The center offers services in the areas of allergy, asthma, cardiology, clinical immunology, COPD, environmenta …
  • Awilco LNG ASA (ALNG):企業の財務・戦略的SWOT分析
    Summary Awilco LNG ASA (Awilco LNG) a subsidiary of Awilhelmsen AS is an oil and gas company that provides LNG transportation programs. The company owns and operates LNG vessels intended for international trading. It offers LNG value chain such as liquefaction, production, regasification, transporta …
  • CA Technologies, Inc.:企業の戦略・SWOT・財務情報
    CA Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary CA Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Vygon SA-医療機器分野:企業M&A・提携分析
    Summary Vygon SA (Vygon) is a medical specialty company that designs, manufactures and markets single use medical and surgical products. It offers products in the areas of paediatrics and neonatology, emergency and intensive care units, anaesthesia, support for post-operative pain relief, vascular a …
  • Target Corp:企業の戦略・SWOT・財務情報
    Target Corp - Strategy, SWOT and Corporate Finance Report Summary Target Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Findel plc:企業の戦略・SWOT・財務分析
    Findel plc - Strategy, SWOT and Corporate Finance Report Summary Findel plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sanchez Midstream Partners LP (SPP):企業の財務・戦略的SWOT分析
    Summary Sanchez Midstream Partners LP (SMP), formerly Sanchez Production Partners LP, a subsidiary of Sanchez Oil & Gas Corp, is an oil and gas company that acquires, develops and operates midstream and other energy related assets. The company offers drilling results, production, and hedging service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆